Member Info for Matador78

Thought I'd humour you

For the record we were also right about :..

Equator-proven
Medalchemy proven
Emmac and Antonio ( We told you about the company being created way before anyone knew it existed yet to have confirmation of ffwd involvement)
Nuuvera IPO -proven

and a whole host of other links and research

Welcome to FFWD have a seat and read up. : )

https://www.apnews.com/8120408090bc46b9a9f8652861398024

In recent years AI companies have begun implementing increasingly sophisticated machine learning techniques to significantly mitigate and, in some cases, eliminate inefficiencies in the current healthcare system,” Naheed Kurji added. “These innovations have accelerated growth of AI in the healthcare industry, and engendered enthusiasm and hope in consumers and patients alike. AAIH will work to collaboratively help bring these new health care advances to patients world-wide.”

AAIH’s founding companies and organizations include Amazon Web Services (AWS), Bayer, Beyond Limits, BlackThorn Therapeutics, The Buck Institute for Research on Aging, Cyclica, Envisagenics, GE Healthcare, Genialis, GSK, Insilico Medicine, Johnson & Johnson, minds.ai, Netrias, NuMedii, Numerate, Nuritas, Owkin, Progenics Pharmaceuticals, Recursion, SimplicityBio, and University of Pittsburgh.

Wealth Whispers.

Look who's giving the closing speech. : )

Canada Cannabis House in Davos Announces Speakers and Schedule Including Ehud Barak - 10th Prime Minister of Israel, and Cannabis Industry Leaders Bruce Linton, Kevin Murphy, Richard Carleton, and Saul Kaye:..

5:45pm - "Closing Remarks - Cannabis 2020 and Beyond"

Featuring: Antonio Costanzo (CEO - EMMAC Life Sciences PLC)

https://twitter.com/biogerontology/status/1087551591375200256

“Until now verifying identities has been a very expensive and often manual process that requires the processing and storage of a lot of sensitive and personal information,” Capital300 said in a statement. “We are excited that Authenteq’s unique technology is disrupting the existing process and will enable affordable and fully automatic identity verification, at the same time ensuring the privacy of users.”
Seed stage venture capital firm Draper Associates was founded by third generation venture capital Tim Draper and is best known for investments in companies such as Tesla, Skype, Baidu, Twitch and Hotmail. The firm has been an active investor in blockchain and crypto startups, backing the likes of Coinbase, Ledger, Factom, and Bancor.
“Until now verifying identities has been a very expensive and often manual process that requires the processing and storage of a lot of sensitive and personal information,” Capital300 said in a statement. “We are excited that Authenteq’s unique technology is disrupting the existing process and will enable affordable and fully automatic identity verification, at the same time ensuring the privacy of users.”
Seed stage venture capital firm Draper Associates was founded by third generation venture capital Tim Draper and is best known for investments in companies such as Tesla, Skype, Baidu, Twitch and Hotmail. The firm has been an active investor in blockchain and crypto startups, backing the likes of Coinbase, Ledger, Factom, and Bancor.

The best place to secure FFWD content....is here.

If you have any friends or family that are interested in investing in Cannabis read on. and actually click on the screen shots and read what's being put in front of you.

https://twitter.com/Tat_TvamAsi/status/1087463343504482305

Beckley Canopy Therapeutics raises £7.4m for cannabis R&D

No logoGeorge Underwood

December 4, 2018



Oxford-based biopharma Beckley Canopy Therapeutics has raised £7.4 million to develop a range of cannabis-based products for the treatment of pain and to help tackle opioid addiction.

Investors include Richard Reed, co-founder of Innocent, billionaire UK investor Jim Mellon and Dr Annalisa Jenkins, biotech entrepreneur and philanthropist.

The company said it will use the investment to investigate the efficacy and safety of cannabis-based medicinal products for people living with addiction, cancer-related pain, and for the reduction of opioid use in the treatment of chronic pain in the UK, Europe, and North America.

This marks the first clinical trial to be announced in the UK since the rescheduling of cannabis-based medicinal products to schedule 2 following a government review earlier this year, meaning that they can now be prescribed by specialist clinicians for patients with unmet clinical needs.

Beckley Canopy Therapeutics was borne out of a partnership between UK drug research institute The Beckley Foundation and Canopy Growth Corporation, the world’s leading cannabis company.

“There is already strong real-world evidence pointing to the potential application of cannabinoids in a wide range of disease areas including in the treatment of people living with certain types of drug dependence, such as opioid addiction,” said Lady Amanda Feilding, founder and director of the Beckley Foundation. “Beckley Canopy’s research presents a timely opportunity to prove the efficacy and safety of cannabis-based treatments in a UK clinical trial setting, for the benefit of people living with cancer pain and opioid drug dependence.”

Cosmo Feilding Mellen, managing director at Beckley Canopy Therapeutics, added: “The rescheduling of cannabis based medicinal products provides the UK with an opportunity to take a leadership role in cannabis regulation, setting a gold standard for patient access that the rest of the world should follow.

“As a new business partnership investing in UK medicine and research, we would like the government to ensure that access to medicinal cannabis is as simple and straightforward as possible for patients.”

Addiction is a growing concern for countries across the world – there are over 190,000 overdose deaths globally each year, with the majority attributable to the use of opioids. The opioid crisis has become a key focus for the US government, with president Donald Trump signing new legislation aimed at promoting research into painkilling drugs that are not addictive, as well as expanding access to treatment for substance use disorders for patients on Medicaid.

https://pharmaphorum.com/news/beckley-canopy-therapeutics-raises-7-4m-for-cannabis-rd/

Morning all, Just a thought for those of you sitting on the sidelines wondering if it's worth it or not.

The average licensing deal for a novel molecule is a cheque for 38 Million dollars.

Insilico Medicine have over 2000 Molecules in their pipeline.

That's a $76,000,000,000 potential.

Round B was expected in April/May although it might have been moved forward.

Paranoir. It's not speculation. It's verified.

Fully understand Goodhand.

yes of course. It's not going to wait. I'm writing on the move.

Guys, I can assure you the plaintiff was Tik Tok

If anyone other than us "Three Amigos" has any kind of interest in the chinese market and understands the implications of how much it means for Factom and Yooya and ultimately Fast Forward holders I'd urge you to start researching it today.

Why today?

The Shareprice is going to wait until you've figured it out. The Market isn't fair in that respect.

You either get a position early and sit it out like the rest of us or you wait for the RNS and stand in the queue hoping to grab a piece.

I find researching the Chinese side of things particularly difficult only because of the language barrier but I have a few friends who are helping me to bridge that gap. If you know anyone who can translate then please introduce them and lets get ahead of the curve.

Buy and Hold

Take it easy O'Donnell don't walk towards the light...We'll still be here when you get back

https://www.marketwatch.com/press-release/global-blockchain-in-healthcare-market-forecast-2019-2027-2019-01-09

Companies mentioned
1. CHANGE HEALTHCARE
2. CHRONICLED, INC.
3. FACTOM INC.

Seriously though,

I'd urge anyone who holds to read through the portfolio and our research and find a very good reason NOT to hold before they hit the sell button.

Vemo
Intensity Therapeutics
Juvenescence
Factom
Leap Gaming
Yooya
Vogogo
Diabetic Boot Company

All of the above have a Niche in their respective markets and anyone holding is lucky enough to the exposure at seed level.

Not much on AIM that's original and hedged against itself.

Can anyone give me a reason to sell?

https://www.pharmaceutical-business-review.com/news/juvenescence-closes-first-tranche-of-series-b-financing-for-further-growth-and-development/